AAN 2021 | Neurofilament light chain as a biomarker in pediatric MS

Predicting disease course is important in multiple sclerosis (MS) as it can be clinically heterogeneous. Identification of informative prognostic biomarkers in pediatric MS would allow tailoring of therapy to best suit an individual. Tanuja Chitnis, MD, FAAN, Brigham and Women’s Hospital, Boston, MA, talks on promising investigations into serum neurofilament light chain (sNfL) as a marker of neuronal damage in adults, and the importance of carrying these studies over to the pediatric setting. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.